Summary The synthesis and degradation of type I and type IlIl interstitial collagens releases several antigenic metabolites, whose measurement allows the metabolism of connective tissue to be evaluated under a variety of different conditions. In this study we investigated the influence of benign and malignant ovarian neoplasms on the metabolism of these collagens. The study population comprised patients with benign (n = 53), borderline (n = 6) or malignant (n = 36) ovarian neoplasms. We quantified the serum, cyst fluid and peritoneal/ascitic fluid concentrations of the amino-terminal propeptide of type (PINP) and IlIl (PIIINP) procollagens, indicators of the synthesis of type and IlIl collagen, respectively and the cross-linked carboxy-terminal telopeptide of type I collagen (ICTP), ani indicator of type I collagen degradation.
ascites formation
The growth and dissemination of malignant neoplasms are accompanied by complex biochemical events that alter collagen metabolism. During tumour growth and dissemination the increased synthesis of proteolytic enzymes with the consequent disruption of collagen architecture is a prerequisite for neoplastic cell invasion and dissemination (Liotta, 1986; van den Hooff, 1986) . Proteolytic phenomena have been the subject of intensive research for over 10 years (Liotta, 1986; van den Hooff, 1986) . However, much less research has focused on the synthesis of extracellular collagens, even although fibrillar collagens are essential components of the extracellular matrix of any tumour. In addition, extensive collagen synthesis is characteristic of the so-called 'desmoplastic' reactions that are often observed surrounding the neoplastic epithelial cells of many solid tumours.
The most abundant soft-tissue collagens are types I and III. At present, specific radioimmunoassays (RIAs) can be used to monitor both the synthesis of type I and type III collagens, and the degradation of type I collagen . The aminoterminal propeptides of type I (PINP) and type III procollagens (PIIINP) are removed during the synthesis of the corresponding collagens. Although some of these propeptides may remain on the surface of the collagen fibres (Fleischmajer et al, 1985) and are released into body fluids during degradation of collagenous matrix network, present techniques measure predominantly the synthesis of the corresponding collagen molecules (Risteli et al, 1988a; Melkko et al, 1996) . The trivalently cross-linked carboxy-terminal telopeptide of type I collagen (ICTP) is a degradation product of the mature type I collagen molecule.
We have previously investigated synthesis of type III collagen with our assay for PIIINP (Risteli et al, 1988b; Kauppila et al, 1989) and that of type I collagen using an assay we have developed that measures levels of the carboxy-terminal propeptide of type I procollagen (PICP) (Zhu et al, 1993) in patients with ovarian neoplasms. In this study we widened our investigations by the inclusion of two new markers; PINP and ICTP. The quantification of levels of the last two antigens enabled us for the first time to measure simultaneously both the synthesis as well as the degradation of type I collagen in this disease, and to compare synthesis synthesized and degraded by similar mechanisms. Serum, peritoneal/ascitic fluid and cyst fluid specimens from ovarian tumour patients were assayed for these markers. The cytokine macrophage colony-stimulating factor 1 (CSF-1) stimulates the proliferation and differentiation of monocytes, is a chemoattractant for macrophages and may be involved in the pathogenesis of ovarian and some other malignancies (Kacinski, 1995) . Neoplastic epithelial cells synthesize CSF-1 and increase CSF-l production through macrophage activation, which in turn may stimulate further growth of the neoplasm, particularly when the tumour cells themselves express receptors for this cytokine (Kacinski, 1995) . Further support for this approach comes from observations that macrophage-conditioned media enhance stromal cell proliferation (Olive et al, 1991) . In endometrial carcinoma, serum concentrations of CSF-1 were found to correlate with serum PIIINP concentrations, suggesting a possible causal link between PIIINP release and CSF-l synthesis (Hakala et al, 1995) .
As CSF-1 is known to be essential for macrophage survival and macrophages play an essential role in fibrillar collagen catabolism and CSF-I is synthesized often at very high levels by many epithelial tumours of female reproductive organs, it was reasonable for British Journal of Cancer (1998) also assayed with the PINP Col 1 (amino-terminal globular region of the amino-terminal propeptide of type I) method, which also detects small-molecular-weight degradation products of PINP molecules Melkko et al, 1996) . The samples for CSF-1 determination were sent frozen to the laboratory in the USA (ERS). CSF-1 was quantified by radioimmunoassay using methods described in detail elsewhere (Gilbert et al, 1989) . The upper limit of the reference interval for serum CSF-1 was 6.1 jig 1-'.
Statistical analysis
Because of the skewed distribution of most variables, we used the Mann-Whitney U-test throughout in the bivariate comparisons. A dot-plot technique was used to present the distribution of the markers. A linear regression model was applied to estimate the relationship between two continuous variables.
RESULTS

Malignant and benign tumours
Comparison of intact PINP, ICTP, PIIINP and CSF-1 in samples from patients with malignant and benign tumours revealed significantly higher concentrations in specimens from ovarian carcinoma patients in all levels, except those of ICTP in the peritoneal/ascitic fluid and CSF-1 in the cyst fluid (Figures 1 and 2 ). Despite the remarkable overlap of the values between the groups, the present results demonstrate that high peritoneal fluid PINP (> 2500 jig 1-'), PIIINP (> 400 jig 1-1) or CSF-1 (> 8 jig 1-1) concentration is characteristic of malignancy, whereas low cyst fluid PINP (< 300 jig 1-1), ICTP (< 0.5 jig 1-1), PIIINP (< 30 jg 1-1) or CSF-1 (<1 jIg 1-l) concentration is typical of benign neoplasms.
The median PINP concentration in ascitic/peritoneal fluid from individuals with a malignant disease was approximately 50 times higher and in cyst fluid eight times higher than that in serum (Table  1) times higher than in serum and remarkably similar in cyst fluid and in serum from both groups of patients. PIIINP concentration was 200-fold higher in ascitic fluid and 30-fold higher in cyst fluid than that in serum from patients with malignant disease. The median PINP and PIIINP concentration in malignant ascites was on average six-to sevenfold higher than in cyst fluid. The median CSF-1 concentration was about 1.5-fold higher in ascitic fluid and in cyst fluid than in serum from patients with malignant ovarian tumour and remarkably similar in serum, peritoneal fluid and cyst fluid from patients with a benign tumour. The data for the six patients with borderline malignancies, presented in Figures 1 and 2 , were not used in any statistical evaluation. The values for borderline tumours were mostly in the same range as those of benign tumours in the serum and peritoneal/ascitic fluid, whereas in the cyst fluid they were predominantly of the same category as the values in malignant tumours.
Correlations
In patients with a malignant tumour, serum ICTP concentration correlated significantly with that in malignant ascites (Figure 3) but not with that in cyst fluid. There was also a significant correlation between the concentration of PINP, but not of PIIINP, in serum and malignant ascites (Figure 3) . The concentration of PIIINP and CSF-1 in ascites or in cyst fluid did not correlate with each other or with serum concentration of any marker. A strong correlation between the concentration of PINP and PINP Col 1 (R2 = 0.82, P = 0.82), and quite similar median levels of PINP Col 1 (58 gg 1-1) (range 25-174) and PINP concentration (47 gg 1-1) (range 16-112) in sera from 25 patients with malignant tumour demonstrated that the majority of PINP molecules in serum appeared in the form of intact PINP.
Clinical findings
The serum concentrations of intact PINP, ICTP, PIIINP and CSF-1 were increased in 10%, 57%, 60% and 50% of patients with ovarian cancer, respectively, without any substantial difference between stages I plus II and stages III plus IV (Figure 4 ) (data not shown for CSF-1). There was also no significant difference in any marker level between the subtypes of epithelial carcinomas. The serum concentrations of PINP and PIIINP but not those of ICTP (Figure 4 ) and CSF-1 (grade 1-2: n = 17, median concentration 4.7 jg 1-1, range 0.4-15 jg 1-1; grade 3: n = 19, median concentration 8.9 jg 1-1, range 0.3-19 jig 1-1) were significantly higher in patients with grade 3 carcinomas than in patients with grade 1-2 carcinomas, suggesting that poorly differentiated tumours stimulate synthesis of fibrillar collagens more than well-differentiated neoplasms do.
DISCUSSION
In this study we used fluid specimens for the intact PINP, ICTP, PIIINP and CSF-1 assays from three sources: ovarian cyst, peritoneal cavity and circulation. The levels of these markers in cyst fluid very probably reflect matrix reactions within the tumour; in peritoneal/ascitic fluid their levels may be consequent to tumourinduced reactions within the peritoneal cavity, whereas those observed in the serum may originate from the tumour, from the peritoneal cavity, from the reactions of the host to ovarian neoplasm or from all of these. In the interpretation of the results, we have put a special emphasis on (a) parallel investigation of synthesis and breakdown of type I collagen; (b) parallel evaluation monitoring their response to therapy (Kylmala et al, 1995) .
*o * * @ Destruction of soft tissues also contributes to the blood pool of this 20 * antigen, and serum ICTP behaves like a tumour marker in 0 advanced ovarian cancer (Santala et al, 1995) . Because the present St 1-11 St III-IV assay identifies only telopeptides with trivalent cross-links it does n=12 n= 17 not detect degradation products of newly formed (Risteli et al, 1997) , less cross-linked type I collagen common in tumour tissue (Kauppila et al, to be published) PINP (35 000) and PIIINP (42 000). In addition, the propeptide molecules detected in PIIINP assay are often present in the ascitic concentrations of ovarian cancer fluid in an unprocessed, immature form of very large molecular grade and clinical stage. The size (Zhu et al, 1994) . The lymphatics are also important for the al value. Gr, grade; St, stage; resorption of PIIINP molecules from abdominal cavity (Jensen et al, 1993) . Any interruption of this route by malignancy may prevent the procollagen molecules to reach the circulation. II collagens using assays Second, ICTP and the procollagen propeptides are cleared by respective molecules, which different mechanisms. The ICTP antigens are cleared from the -ndothelial scavenger recepblood by the kidneys , whereas PIIINP pe I and type III procollagen and PINP are eliminated by the scavenger receptors of the liver r ascites formation; (d) the endothelial cells . Third, the low ascitic en metabolism; and (e) the fluid-serum concentration ratio of ICTP may reflect a low rate of ays. degradation relative to the rate of its synthesis in this disease in British Journal of Cancer (1998) general. Alternatively, this finding is specific only for the conditions the specimens were taken as ascites was mostly from patients who were operated on soon after its appearance. At this stage, tumours usually manifest a rapid intra-abdominal growth rate.
Because PINP may be degraded to smaller antigenic forms in patients with catabolic status , we evaluated in more detail the PINP molecules in the serum from patients with malignant ascites using the PINP Col 1 assay, which measures both the intact propeptide and its degradation products. This assay gave only slightly increased concentrations relative to the assay for intact PINP, confirming that the latter assay is reliable for comparisons of serum and ascitic fluid PINP concentrations.
CSF-1 might be causally linked to enhanced collagen metabolism in ovarian cancer (Jennings et al, 1994) , as we had supposed to be the case for endometrial cancer (Hakala et al, 1995 (Kacinski, 1992 (Kacinski, , 1995 , which are known to stimulate collagen production in the fibroblastic cells (Sporn and Roberts, 1992 (Kacinski, 1995) , and that ovarian and endometrial cancer behave differently in this respect, may explain the conflicting finding.
CSF-1 has an important role in the regulation of the neoplastic disease activity of ovarian cancer (Kacinski, 1992 (Kacinski, , 1995 , and it has potential to be a practical tumour marker in patients with gynaecological (Kacinski et al, 1989 (Kacinski et al, , 1990 Hakala et al, 1995) and other malignant diseases (Janowska-Wieczorek et al, 1991). We have confirmed here that CSF-I concentration in ascitic fluid is increased in patients with ovarian carcinoma (Kacinski, 1992 (Kacinski, , 1995 Price et al, 1993) . The present median concentration of CSF-I in ascites was the same as in the study of Price et al (1993) . Serum CSF-1 concentrations were elevated only in 50% of the present patients. The higher frequency, approximately 70% in previous reports on patients with clinically detectable ovarian carcinoma, is possibly due to different patient populations.
We also showed that high concentration of CSF-1 (8,g 1-' or more), PINP (2500 jig 1-' or more) or PIIINP (400,g 1-1 or more) in peritoneal fluid is diagnostic of ovarian cancer. On the other hand, low cyst fluid values of any marker is indicative of benign tumour. The measurement of the ascitic and cyst fluid concentration of CSF-1 or any of the above-mentioned antigenic collagen metabolites might help differentiate benign from malignant tumours. The grade of differentation of the tumour was a more important determinant for the expression of type I and type III collagen metabolites than the extent of disease. The concept that the synthesis of fibrillar collagens is most evident in anaplastic ovarian malignancies gets supports from our immunohistochemical studies (Zhu et al, 1995) and investigations applying in situ probes for ot1 and a2 chains of type I collagen and for a1 of type III collagen . Besides the fibroblasts, some anaplastic malignant cells seem to participate in the synthesis of collagen fibres (Zhu et al, 1995; Kauppila et al, 1996) . The mesothelial cells in the peritoneum also probably contribute to these reactions with growth factor (e.g. CSF-1) expression (Jennings et al, 1994) . The expression of the enzymes responsible for the destruction of fibrillar collagens is also most prominent in anaplastic tumours (Autio-Harmainen et al, 1993 ).
In conclusion, our study provides several independent lines of evidence demonstrating that the greatly enhanced synthesis of fibrillar collagens is a characteristic of ovarian malignancy, as is the simultaneously enhanced breakdown of soft tissue and its collagenous framework.
